Tablets: May be taken with or without food, swallowed whole and not chewed, broken, or crushed.
Oral solution: must be taken with food.
KALETRA oral solution is not recommended for use with polyurethane feeding tubes due to potential incompatibility. Feeding tubes composed of silicone or polyvinyl chloride (PVC) can be used.
Adults :
Pediatric Patients (14 days and older) :
* KALETRA once daily dosing regimen is not recommended in pediatric patients.
* Twice daily dose is based on body weight or body surface area.
Concomitant Therapy in Adults and Pediatric Patients:
* Dose adjustments of KALETRA may be needed when co-administering with efavirenz, nevirapine, or nelfinavir.
* KALETRA oral solution should not be administered to neonates before a postmenstrual age (first day of the mother’s last menstrual period to birth plus the time elapsed after birth) of 42 weeks and a postnatal age of at least 14 days has been attained
Pregnancy ( 2.5):
* 400/100 mg twice daily in pregnant patients with no documented lopinavir-associated resistance substitutions.
* There are insufficient data to recommend a KALETRA dose for pregnant patients with any documented KALETRA-associated resistance substitutions.
* No dose adjustment of KALETRA is required for patients during the postpartum period.
drug label
Kaletra prescribing information
Have more Kaletra questions?
Submit MSL Request
Learn More
Your request will be referred to the appropriate AbbVie Inc. medical professional, such as a Kaletra pharmaceutical rep; Medical Science Liaison (MSL) or medical affairs.
Need to report a Kaletra issue?
ONLINE FORMReport adverse event
Learn More
You can report a Kaletra adverse event on MedWatch, the FDA's medical product safety reporting program for health professionals, patients and consumers.
prior authorization
Kaletra Prior authorization resources
NOT PROVIDED BY BRANDComplete Letter of Medical Necessity
NOT PROVIDED BY BRANDCoverage Authorization Request
NOT PROVIDED BY BRANDCoverage Authorization Appeals
Learn More
If available, these templates are provided by the brand to help you navigate insurance, especially with newer drugs.
Benefits investigation
NOT PROVIDED BY BRANDBenefits investigation resources
Learn More
Benefits investigations are conducted to determine whether a therapy is covered under a patient's insurance, if a prior authorization is required, and which specialty pharmacies are preferred.
Reimbursement help (FRM)
NOT PROVIDED BY BRANDReimbursement help (FRM) resources
Learn More
Some brands offer a field reimbursement manager who will work with your clinical staff and preferred pharmacy to help make sure patients don't fall through the cracks.
financial assistance
Kaletra Financial assistance options
Co-pay savings program
commercial only
Enroll in Patient Savings Program
Rebate Form
Learn More
Overview
Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance
How to sign up
Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Bridge program
commercial only
Learn More
Overview
Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)
Patient benefit
100% free (outside of insurance)
Patient eligibility
HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries
How to sign up
Typically HCP assisted enrollment (via form)
Foundation programs
under insured
no insurance
goverment insurance
65+
Learn More
Overview
Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
Patients submit proof of out-of-pocket drug costs to charities for reimbursement
patient education
Kaletra Patient education
Getting started on Kaletra
NOT PROVIDED BY BRANDInstructions For Use: Kaletra
Patient toolkit
Patient Resources
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Learn More
Other resources brands publish to help support patients and caregivers.
people also ask
Kaletra FAQs
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available
Can't find what you're looking for?
Our trained staff can help you:
Please note:
Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.